Efficacy of GUM® Hydral versus Biotène® Oralbalance mouthwashes plus gels on symptoms of medication-induced xerostomia: a randomized, double-blind, crossover study
- PMID: 28353023
- DOI: 10.1007/s00784-017-2096-0
Efficacy of GUM® Hydral versus Biotène® Oralbalance mouthwashes plus gels on symptoms of medication-induced xerostomia: a randomized, double-blind, crossover study
Abstract
Objectives: The objective of this study is to determine the efficacy of GUM® Hydral versus Biotène® Oralbalance (both a mouthwash plus gel) on the subjective burden and clinical symptoms of patients with medication-induced xerostomia.
Materials and methods: Subjects (N = 40) with medication-induced xerostomia (minimum 4/10 mm visual analog scale [VAS]) were randomized to treatment with GUM Hydral or Biotène Oralbalance mouthwash, both with gel, for 28 days. Subjects then entered a 21-day wash-out period, before crossing over to the other treatment for 28 days. Outcomes measured included the VAS, German Oral Health Impact Profile (OHIPG)-14, Xerostomia Questionnaire (XQ), after-use questionnaire, and clinical parameters.
Results: Both GUM Hydral and Biotène Oralbalance significantly (p < 0.05) reduced VAS, OHIPG-14 total score and single items, and XQ Part 1 (oral dryness, oral pain, taste loss) and Part 2 items. GUM Hydral also significantly reduced the XQ Part 1 dysphagia score, while Biotène Oralbalance significantly reduced the halitosis organoleptic score and plaque index. Significant increases in saliva secretion did not reach clinical relevance. No significant between-group differences were observed, apart from OHIPG-14 items "trouble pronouncing words" and "uncertainty" in favor of GUM Hydral. No adverse effects were reported.
Conclusions: Both products effectively improve oral health and xerostomia-related quality of life. However, they cannot completely substitute the continuous in-mouth secretion of saliva, and symptomatic relief is temporary. Product selection will be based on personal preference.
Clinical relevance: Both products diminish xerostomic burden and should be part of the management strategy. Affected patients should be informed of these treatments, since no adverse effects were reported.
Keywords: Gel; Medication-induced xerostomia; Mouthwash; Oral health-related quality of life; Xerostomia questionnaire; Xerostomic burden.
Similar articles
-
A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer.Support Care Cancer. 2000 May;8(3):203-8. doi: 10.1007/s005200050286. Support Care Cancer. 2000. PMID: 10789961 Clinical Trial.
-
Efficacy and safety of a new oral saliva equivalent in the management of xerostomia: a national, multicenter, randomized study.Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Mar;119(3):301-9. doi: 10.1016/j.oooo.2014.12.005. Epub 2014 Dec 12. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015. PMID: 25617119 Clinical Trial.
-
A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia.Eur J Cancer Care (Engl). 2005 Sep;14(4):319-26. doi: 10.1111/j.1365-2354.2005.00587.x. Eur J Cancer Care (Engl). 2005. PMID: 16098116 Clinical Trial.
-
Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety.Oral Dis. 2002 Jan;8(1):23-9. doi: 10.1034/j.1601-0825.2002.1o781.x. Oral Dis. 2002. PMID: 11936452 Review.
-
Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.Support Care Cancer. 2003 Apr;11(4):226-31. doi: 10.1007/s00520-002-0409-5. Epub 2002 Oct 22. Support Care Cancer. 2003. PMID: 12673460 Review.
Cited by
-
Accuracy of a questionnaire on xerostomia as a screening tool for hyposalivation.Int Dent J. 2020 Dec;70(6):427-434. doi: 10.1111/idj.12586. Epub 2020 Aug 23. Int Dent J. 2020. PMID: 32830311 Free PMC article.
-
A randomised controlled pilot trial of two interventions to manage dry mouth in pre-operative elective surgical patients.Pilot Feasibility Stud. 2020 Jun 24;6:89. doi: 10.1186/s40814-020-00630-0. eCollection 2020. Pilot Feasibility Stud. 2020. PMID: 32587752 Free PMC article.
-
Comparative Mucosal Wetting Capacity of Novel and Commercial Saliva Substitute Formulations: An in vitro Study.Clin Cosmet Investig Dent. 2025 Mar 19;17:159-167. doi: 10.2147/CCIDE.S514583. eCollection 2025. Clin Cosmet Investig Dent. 2025. PMID: 40124576 Free PMC article.
-
Oral peroxidases: From antimicrobial agents to ecological actors (Review).Mol Med Rep. 2021 Jul;24(1):500. doi: 10.3892/mmr.2021.12139. Epub 2021 May 13. Mol Med Rep. 2021. PMID: 33982776 Free PMC article. Review.
-
A conceptual model of oro-facial health with an emphasis on function.J Oral Rehabil. 2021 Nov;48(11):1283-1294. doi: 10.1111/joor.13250. Epub 2021 Sep 12. J Oral Rehabil. 2021. PMID: 34462948 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical